Skip to main content
TipRanks
Go Ultimate75% OFF

OncoTherapy Science (30O) AI Stock Analysis

0 Followers
DE:30O

OncoTherapy Science

(Frankfurt:30O)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-Free Balance SheetZero debt and a reported 0.0 debt-to-equity ratio reduce fixed financial obligations and preserve flexibility while the company funds oncology research. The increased equity cushion in 2026 provides additional balance-sheet support, although losses remain a constraint.
Negative Factors
Revenue Decline and VolatilityRevenue has been volatile and declined in 2026 versus 2025, while the reported revenue-growth figure is -25.6%. A shrinking and uneven top line makes it harder to absorb research costs and establish a dependable base for future operating leverage.

OncoTherapy Science (30O) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%DE:30O-30.23%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 32.85M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-6.1
Beta (1Y)
1.27
Revenue Growth
-32.99%
EPS Growth
24.71%
Country
Germany
Employees
46
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound th...

OncoTherapy Science Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:30O against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4565JP:456563NeutralJPY 148.18B-26.75-8.51%―23.72%12.48%
JP:4579JP:457962NeutralJPY 19.26B44.36――31.84%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4588JP:458851NeutralJPY 205.78B-125.84――1748.97%35.11%
JP:4587JP:458748NeutralJPY 137.62B-47.20-5.85%―14.25%50.07%
JP:4571JP:457141NeutralJPY 5.92B-4.14-39.57%―48.92%-46.91%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%DE:30OJP:4587JP:4565JP:4571JP:4579JP:4588Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:30O and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:30OOncoTherapy Science, Inc.0.06-0.03-34.07%
JP:4587Peptidream 1060.00-566.00-34.81%
JP:4565Sosei Group Corporation1600.00738.0085.61%
JP:4571NanoCarrier Co., Ltd.65.00-79.00-54.86%
JP:4579RaQualia Pharma Inc.740.0051.007.40%
JP:4588Oncolys BioPharma, Inc.6940.005975.00619.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.